News & Updates
Filter by Specialty:
Small wins for amlitelimab in STREAM-AD
The experimental drug amlitelimab has scored positive outcomes in the double-blind, placebo-controlled phase IIb STREAM-AD study evaluating it as a treatment for moderate-to-severe atopic dermatitis (AD).
Small wins for amlitelimab in STREAM-AD
23 Oct 2023
Do alpha-1 receptor blockers help prevent COVID-19 hospitalization?
Frequent use of alpha-1 receptor blockers is neither harmful nor protective against the risk of uncomplicated or severe COVID-19 hospitalization, a study has shown.
Do alpha-1 receptor blockers help prevent COVID-19 hospitalization?
22 Oct 2023
Nonsteroidal cream brings early relief in atopic dermatitis itch
In children and adults with moderate-to-severe atopic dermatitis, applying tapinarof cream 1% helps reduce itch within 24 hours, according to the results of the phase III trials ADORING 1 and 2.
Nonsteroidal cream brings early relief in atopic dermatitis itch
21 Oct 2023
Roflumilast serves up weight-loss benefit for patients with psoriasis
In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.
Roflumilast serves up weight-loss benefit for patients with psoriasis
20 Oct 2023
Beta strain-containing bivalent vaccine protects against various SARS-CoV-2 variants
A Beta variant-containing vaccine conferred protection against different SARS-CoV-2 variants, with an acceptable safety profile in adults <60 years, a phase III trial has shown.
Beta strain-containing bivalent vaccine protects against various SARS-CoV-2 variants
20 Oct 2023
GLP-1RA, SGLT2i superior to DPP-4i at preventing stroke, death in T2D patients
Among type 2 diabetes (T2D) patients with and without comorbid cardiovascular disease, those who have been newly initiated to glucagon-like peptide-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter 2 inhibitors (SGLT2i) appear to enjoy greater reductions in the risks of stroke and death when compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), suggests a study.
